Antova: Began Phase II trial

Biogen Inc. (BGEN), Cambridge, Mass. Product: Antova Business: Autoimmune/Inflammation Therapeutic category: Antibody, Immune suppression Target: CD40 ligand Description: Humanized anti-CD40 ligand ...